Gauging Analysts’ Views on Tesaro Stock
In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.
Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.
Tesaro Expects These Key Research Pipeline Milestones in 2019
As per Tesaro’s (TSRO) third-quarter earnings conference call, the company is anticipating results from Phase 1/2 trial, AVANOVA.
Zejula Is a Major Growth Driver for Tesaro
In its third-quarter earnings conference call, Tesaro (TSRO) has forecasted Zejula’s revenues for fiscal 2018 to fall in the range of $233 million to $238 million.
What Are Tesaro’s Revenue Projections for Fiscal 2018?
In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.
PTC Therapeutics to Acquire Agilis Biotherapeutics
On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.
Talazoparib and Pidilizumab May Prove Complementary to Pfizer’s Existing Oncology Drugs
Medivation has added its robust research pipeline with two promising investigational drugs, Talazoparib and Pidilizumab, to Pfizer’s oncology portfolio.